Ildong Pharmaceutical operates about 20 R&D pipelines

Five new drug candidates, including diabetes drugs and anticancer drugs, enter the clinical stage

R&D costs have tripled in two years despite losses for seven consecutive quarters

Cooperate with 3 subsidiaries to improve efficiency and speed of new drug development

Ildong Pharmaceutical is using an aggressive new drug development strategy, risking a deficit for seven consecutive quarters.

 

Ildong Pharmaceutical is operating about 20 new drug pipelines, and five of them have entered the clinical stage.

 

It is focusing on enhancing the performance and possibility of new drugs by establishing a cooperation system with R&D subsidiaries.

 

According to IR data from Ildong Pharmaceutical on the 28th, the company has a total of 20 new drug pipelines at the group level.

 

New drugs are being developed in areas such as metabolic diseases, NASH, COVID-19, ophthalmic diseases, neurological diseases, cardiovascular diseases, and cancer.

 

Among them, five cases, including diabetes treatments, COVID-19 treatments, acute migraine treatments, and anticancer drugs, have entered the clinical stage.

 

In the case of IDG16177, a new drug candidate for type 2 diabetes treatment, it entered phase 1 clinical trial in July last year after obtaining approval from a German pharmaceutical and medical device management institution.

 

IDG16177 is a new drug candidate in the family of GPR40 agents with a mechanism to regulate blood sugar by activating GPR40 (G protein-binding receptor 40) in pancreatic beta cells, minimizing the risk of hypoglycemia due to drug administration Idience, a subsidiary of Ildong Holdings, is conducting a phase 2 clinical trial of the new anticancer drug candidate IDX-1197 that was handed over from Ildong Pharmaceutical.

 

IDX-1197 is a target anticancer drug candidate that selectively acts on a deep poly ADP-ribose polymerase (PARP) enzyme related to cancer production to suppress cancer cells.

 

It was developed by Ildong Pharmaceutical on its own and handed over the rights to .

 

is a bio-venture founded by Ildong Holdings in May 2019.

 

It advocates NRDO bioventures that are dedicated to development without discovering new drugs directly.

 

In November last year, Ildong Pharmaceutical started clinical trials in Korea on Shionogi's oral COVID-19 treatment candidate "S-217622" and is currently undergoing phase 3 clinical trials.

 

Reyvow, a migraine treatment that Ildong Pharmaceutical secured in Korea, was approved by the Ministry of Food and Drug Safety in May after a phase 3 clinical trial in Korea.

 

Reyvow is the first migraine treatment to act as a serotonin (5-HT) 1F receptor.

 

Ildong Pharmaceutical signed a development partnership with CoLucid in the U.S.

 

in 2013 to secure domestic copyright.

 

The new drug candidate for NASH treatment ID119031166 is being developed globally.

 

ID119031166 is a NASH treatment with the FXRagonist mechanism that activates the receptor by combining it with farnesoid X receptor (FXR) and aims to enter phase 1 clinical trials overseas by the end of this year.

 

Ildong Pharmaceutical predicted that the gastroesophageal reflux disease treatment ID120040002 and the dry eye disease treatment ID110410395 will enter clinical trials within this year.

 

Ildong Pharmaceutical invested 34.1 billion won, the largest amount ever, in R&D expenses in the second quarter.

 

21.0% of sales were spent on R&D investment.

 

It has tripled in two years from 11.6 billion won in the second quarter of 2020.

 

During this period, Ildong Pharmaceutical invested 176 billion won in R&D.

 

Ildong Pharmaceutical is also using a strategy to increase the efficiency and speed of new drug development by establishing a cooperative system with three unlisted bio-ventures such as Idience, AIMS BioScience, and iLeadBMS.

 

iLeadBMS succeeded in attracting 40 billion won in investment last year.

 

Last month, it received a total of 65 billion won since its launch, including investments from Ildong Holdings.

 

The investment secured by iLeadBMS is expected to be used as a resource for developing new drugs.

 

Ildong Holdings acquired AIMS BioScience, a new drug development strategy consulting firm, in December 2019.

 

AIMS BioScience is responsible for providing advice on the development of new drugs to Ildong Pharmaceutical, Idience, and iLeadBMS.

 

It is a method of providing consulting when new drug development companies request AIMS BioScience for strategic advice on providing development data.

 

iLeadBMS, acquired by Ildong Pharmaceutical last year, plays another role in the development of new drugs in the group.

 

Founded in December 2020, iLeadBMS is a bio-venture that develops new drugs in the field of low molecular compounds.

 

It started as an in-house venture centered on Ildong Pharmaceutical researchers and launched an independent corporation in 2020.

 

In July last year, Ildong Pharmaceutical invested 13 billion won in cash to secure a 40.0% stake in iLeadBMS by participating in a paid-in capital increase.

 

iLeadBMS is developing new drugs using low molecular compound pharmaceutical chemistry in various fields such as glaucoma, liver cancer, non-alcoholic fatty liver, biliary disease, Parkinson's disease, glaucoma, breast cancer, Alzheimer's disease, Parkinson's disease, and metastatic breast cancer.

 

Ildong Holdings is also planning a scenario to increase the success rate of new drug development by handing over the new drug candidate materials derived by iLeadBMS to Idience.